IVC blood clot filters are medical devices placed in the inferior vena cava and are designed to catch blood clots and stop them from traveling to the heart or lungs. The inferior vena cava is a vein that returns blood to the heart from the lower portion of the body. In certain people, blood clots from in vessels in the legs and pelvis and travel through the vena cava and into the lungs. Once the clots reach the lungs they cause a condition known as pulmonary embolism. This condition, if not immediately treated, presents grave risk to human life and often results in death. IVC blood clot filters were originally designed to prevent this condition from ever occurring.
However, recent studies have shown that the IVC blood clot filters do not work. In fact, the filters have been shown to double the risk of pulmonary embolism, the very condition which they are intended to prevent. Worse still, these filters present an increased risk of fracturing, titling within the inferior vena cava, perforating the wall of the inferior vena cava (frequently penetrating into other organs and tissues such as the aorta and duodenum), and migrating through the body. Many IVC blood clot filter lawsuits have been filed in state and federal courts around the country as a result of these dangerous side effects.
Call our office to discuss filing an IVC blood clot filter lawsuit 855 FARR LAW (941-639-1158).
IVC blood clot filter devices come in both retrievable and permanent models. The permanent models are implanted into a patients inferior vena cava and are designed to remain there for the duration of the patient’s life. The retrievable models are temporary and designed to be removed by a doctor after a patient’s risk of developing blood clots has diminished. Many of the temporary IVC blood clot filter manufacturers, including C.R. Bard, Cook Medical, and many others, sought approval from the FDA under section 510(k) of the Medical Device Amendment. Section 510(k) allows a manufacturer to market and sell a device if the manufacturer can prove it is similar to another device that is already on the market. If the manufacturer can prove their device is like another already on the market, the manufacturer does not have to formally test the device or prove the safety or the effectiveness of the device to the FDA.
C.R. Bard, Cook Medical, and may other manufacturers placed their retrievable IVC blood clot filter devices on the market for sale to the public without adequately testing the device. This is likely because the manufacturers knew medical testing would not support that the devices were safe or effective. In fact, medical testing confirms that both permanent and retrievable IVC blood clot filter devices fail at an abnormally high rate. Overtime, the pressure of a person’s blood traveling through the inferior vena cava can cause the spider-like arms of the device to fracture, tilt, perforate the vena cava wall, and/or migrate, and thus cause serious injury. Some of these injuries include infection, thrombosis, embolization of IVC filter device components, caval thrombosis, pulmonary embolism, trauma, and death.
Despite their knowledge of the defects, C.R. Bard, Cook Medical, and many other manufacturers failed to disclose, and in fact concealed these risks from patients. The manufacturers then continued to promote their IVC blood clot filters despite the absence of adequate clinical trials to support the long-term safety of the retrievable IVC blood clot filter and even after later-performed studies have shown them to lack such safety.
Our law firm is currently investigating IVC blood clot filter cases. Below is a list of many common manufacturers and models of IVC blood clot filter devices.
If you or a loved one was implanted with an IVC blood clot filter and suffered a severe side effect caused by the device fracturing, titling within the inferior vena cava, perforating the wall of the inferior vena cava and into other organs and migrating through the body, contact our office to discuss filing an IVC blood clot filter lawsuit 855 FARR LAW (941-639-1158).